论文部分内容阅读
目的 通过多中心、开放性临床观察 ,对多巴胺能受体激动剂α 二氢麦角隐亭的临床疗效进行评估。 方法 将 60例患者分为单用α 二氢麦角隐亭组 (单用组 ) 2 7例和α 二氢麦角隐亭与复方左旋多巴合用组 (合用组 ) 3 3例 ,观察治疗前后改良统一帕金森病评定量表 (unificdParkinson’sdiseaseratingscale ,UPDRS)评分的改善程度和临床总印象的评定 ,因不良反应和原因不明而失访 2例。 结果 单用组和合用组患者的临床症状均有不同程度改善。单用组中显著进步 7例(2 8 0 % ) ,合用组 13例 (3 9 4% )。治疗前后改良MUPDRS评分改善程度在单用组平均为 5 0 1分 ,合用组为 6 3 9(P <0 0 0 0 1)。临床总印象评定中 ,医生和患者对疗效评价明显好转在单用组皆为2 1 7% ,而在合用组中分别为 2 1 2 %和 3 0 3 %。用α 二氢麦角隐亭治疗前后血常规、肝肾功能检查结果皆在正常范围内 ,心率、血压和心电图未见明显的变化 ,未发现有位置性低血压者。 结论 α 二氢麦角隐亭对改善帕金森病的症状有效 ,无明显不良反应 ,将为治疗帕金森增加一可供选择的有效药物
Objective To evaluate the clinical efficacy of dopamine agonist α-dihydroergocryptine through a multicenter, open-label clinical observation. Methods Totally 60 patients were divided into two groups: α2 dihydroergocrinum group (single use group), 27 patients and α2 dihydroergocrinum plus compound levodopa group (combined group), 3 3 patients were observed before and after treatment to improve Uniform Parkinson’s Rating Scale (unificd Parkinson’s disease rating scale, UPDRS) score improvement and the total clinical impression of the assessment, because of adverse reactions and unexplained and lost two cases. Results The clinical symptoms of both single-use group and combined-use group were improved to some extent. Seven patients (280%) improved significantly in the single-use group and 13 (394%) in the combined use group. Before and after treatment, the improvement of MUPDRS score was improved on average in the single-use group and 6 3 9 in the combined group (P <0 0 001). In the overall clinical impression assessment, the marked improvement in the efficacy evaluation by both doctors and patients was 21.7% in the single-use group and 21.2% and 33.0% in the combined group, respectively. With α-dihydroergocryptine before and after treatment of blood, liver and kidney function test results are within the normal range, heart rate, blood pressure and ECG showed no significant change, no place-type hypotension was found. Conclusions α-dihydroergocryptine is effective in improving the symptoms of Parkinson’s disease with no obvious adverse reactions, which will provide an effective alternative for the treatment of Parkinson’s disease